13 November 2023 - Biocon Biologics has announced that MHRA in the UK has granted marketing authorisation for Yesafili, a biosimilar of aflibercept.

Yesafili is intended for the treatment of neovascular age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion, visual impairment due to diabetic macular oedema and visual impairment due to myopic choroidal neovascularisation.

Read Biocon press release